Table 1.
Decompensated on initial presentation to healthcare, total n=52 | Compensated on initial presentation to healthcare, total n=29 | p value | |
---|---|---|---|
Age, years, median (IQR) | 59.0 (55.0–62.0) | 57.2 (53.0–63.0) | 0.752a |
Encephalopathy, n (%) | 12 (23.1) | 10 (34.5) | 0.269b |
Ascites, n (%) | 33 (63.5) | 14 (48.3) | 0.184b |
Varices, n (%) | 19 (36.5) | 11 (37.9) | 0.901b |
Hepatocellular carcinoma, n (%) | 14 (26.9) | 2 (6.9) | 0.041c |
Ischemic heart disease, n (%) | 3 (5.8) | 1 (3.4) | >0.999c |
Vascular disease, n (%) | 3 (5.8) | 1 (3.4) | >0.999c |
Diabetes, n (%) | 40 (76.9) | 27 (93.1) | 0.075c |
Hypertension, n (%) | 20 (38.5) | 15 (51.7) | 0.248b |
Hypercholesterolaemia, n (%) | 4 (7.7) | 5 (17.2) | 0.270c |
Platelets, × 109/L, median (IQR) | 115.0 (82.0–186.0) | 120.0 (65.0–149.0) | 0.198a |
International normalised ratio, median (IQR) | 1.3 (1.1–1.4) | 1.4 (1.2–1.5) | 0.280a |
Sodium, mmol/L, median (IQR) | 139.0 (136.0–141.5) | 139.5 (137.0–143.5) | 0.514a |
Creatinine, μmol/L, median (IQR) | 84.0 (67.0–118.5) | 83.5 (68.5–110.5) | 0.766a |
Bilirubin, μmol/L, median (IQR) | 24.0 (11.0–44.0) | 30.0 (11.5–48.0) | 0.528a |
Alanine aminotransferase, U/L, median (IQR) | 35.0 (25.5–44.0) | 28.5 (20.0–44.0) | 0.106a |
Aspartate aminotransferase, U/L, median (IQR) | 46.0 (31.0–59.5) | 46.0 (35.5–58.0) | 0.562a |
Fibrosis-4 score, mean±SD | 4.37±3.17 | 5.60±3.03 | 0.099d |
Non-alcoholic fatty liver disease fibrosis score, mean±SD | 1.637±1.657 | 2.371±1.370 | 0.057d |
UK Model for End-Stage Liver Disease score, mean±SD | 52.4±5.6 | 53.4±6.1 | 0.443d |
Model for End-Stage Liver Disease score, median (IQR) | 13.0 (10.0–17.0) | 16.0 (11.5–18.0) | 0.111a |
a = continuous data analysed using Mann–Whitney U test;
b = categorical data analysed using Pearson's χ2;
c = categorical data analysed using Fisher's exact test;·
d = continuous data analysed using an independent t-test; IQR = interquartile range; SD = standard deviation.